KR101886337B1 - Antiviral composition for influenza virus comprising lactobacillus plantarum dsr m2 as an active material - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for an antiviral against influenza virus containing Lactobacillus plantarum as an active ingredient. More specifically, the Lactobacillus plantarum DSR M2 of the present invention is excellent in antiviral activity against influenza virus, and therefore, the pharmaceutical composition containing the same as an active ingredient can be used for influenza virus, cold, sore throat, Bronchitis, pneumonia, avian influenza, swine flu, chlorophyll, and the like.
Lactobacillus plantarum DSR M2, which exhibits the antiviral activity described above, may be usefully used in beverage, fermented food, health functional food, and the like, food composition, food additive composition, feed composition or feed additive composition.

Description

TECHNICAL FIELD [0001] The present invention relates to an antiviral composition for influenza virus containing Lactobacillus plantarum DSR M2 as an active ingredient.

The present invention relates to a pharmaceutical composition for an antiviral against influenza virus containing Lactobacillus plantarum as an active ingredient. The present invention also relates to a food composition, a feed composition or a cleaning composition for preventing or ameliorating an influenza virus infectious disease containing Lactobacillus plentarium as an active ingredient.

Influenza virus is the causative agent of the flu, an acute respiratory infectious disease, and one of the pathogens considered to be very important in public health.

The seasonal influenza virus, which consists of the H1N1 and H3N2 subtypes of influenza A virus and the influenza B virus of Victoria and Yamagata lineage, is in winter every year and is causing great damage to people. According to the World Health Organization (WHO), about 3 million to 5 million people worldwide are infected with the seasonal influenza virus each year and suffer from serious illness, of which about 250,000 to 500,000 people are known to die.

The pandemic of influenza viruses causes more damage. The influenza virus pandemic, which occurred in 1918, killed some 50 million people, and the influenza virus pandemic, which occurred in 1957 and 1968, is known to have killed about 1 million people. Humans experienced severe personal injury, economic damage and social disruption in the pandemic caused by the 2009 influenza virus.

Avian influenza virus is also considered a serious threat. Until now, there have been reports of persistent human infections of avian influenza virus. Especially, 59% of the highly pathogenic H5N1 avian influenza virus and 32% of the H7N9 avian influenza virus have been analyzed, which is closely monitored by WHO.

Although the most effective way to prevent such influenza viruses is known as vaccination, only the vaccine has a limitation in controlling the damage caused by the influenza virus. Despite vaccination against seasonal influenza virus, there are 250,000 to 500,000 deaths worldwide each year.

Influenza vaccines are produced according to a production system that anticipates viruses that will be outbred in winter due to the nature of the antigenic variation of influenza viruses, and then produces vaccines against them. Therefore, there may be cases where the vaccine produced does not coincide with the influenza virus antigens of the winter season, and it may not protect people effectively against influenza virus infection. Also, if the swine flu virus is suddenly outbreak at an unpredictable time, it is difficult to respond quickly to the vaccine.

The use of antiviral agents could overcome the limitations of these vaccines. In fact, oseltamivir (NA inhibitor, NAI), which inhibits neuraminidase (NA), one of the surface glycoproteins of influenza virus, before the preparation of a sufficient dose vaccine in the pandemic of the new influenza virus in 2009, Tamiflu ^® ) has been widely prescribed as an effective swine influenza virus control. According to a recent study, oseltamivir's prescription at the time of 2009 was found to effectively protect people from the swine influenza virus.

Despite the advantages of such antiviral agents, the continued use of antiviral agents can lead to the emergence of antiviral resistant influenza viruses. In fact, the seasonal influenza A (H1N1) influenza virus (A / Birsbane / 59/2007), which acquired resistance to the NAI, oseltamivir, between 2007 and 2009, became popular worldwide. This situation is considered to be highly likely to occur in the current influenza virus, and in fact, the domestic (Disease Control Headquarters) has reported a case of isolating a new influenza virus resistant to oseltamivir. It is also known that influenza B virus is less susceptible to NAI than influenza A virus.

Therefore, it is very urgent to develop an adjuvant which can exhibit a synergistic effect when it is used together with a new antiviral agent or antiviral agent which can be effectively used when a virus having resistance to an antiviral agent is generated. The development of new antiviral or antiviral adjuvants can create great economic benefits, and many researchers and pharmaceutical companies around the world are now spurring the development of new antiviral drugs.

In Korea, too, there is a great need to develop new antiviral drugs with domestic technology. In order to accumulate technologies unique to domestic antiviral drug development and to reduce dependence on foreign countries, There is an urgent need for research for exploring and exploring.

According to a number of recently published research papers, lactic acid bacteria have been shown to inhibit influenza virus infection and to enhance the immunogenicity of influenza vaccines. From this point of view, kimchi and kimchi-derived lactic acid bacteria, which are representative fermented foods of Korea, which have abundant lactic acid bacteria, have a high possibility of being developed as a pharmaceutical adjuvant having antiviral efficacy.

Therefore, if new antiviral substances are developed by using lactic acid bacteria derived from kimchi and kimchi, which are highly likely to be antibiotic-effective drugs, foreign dependence on raw materials and technology can be greatly reduced and economic benefits Of the total population. For example, in 2009, Roche was reported to have earned about $ 900 million in sales of Tamiflu ^® .

Ultimately, if Kimchi lactic acid bacteria, which can effectively inhibit influenza viruses, are developed, it will be possible to protect the Korean people from the risk of influenza virus rapidly in situations where it is not possible to quickly obtain basic treatment agents in the event of a pandemic influenza virus .

Accordingly, the inventors of the present application confirmed that Lactobacillus plantarum DSR M2 lactic acid bacteria inhibits the growth of influenza virus while studying lactic acid bacteria that can effectively inhibit influenza virus.

Korean Patent No. 10-1287120

The present invention is to provide an antiviral pharmaceutical composition for influenza virus comprising as an active ingredient a plant-derived lactic acid bacterium.

Another object of the present invention is to provide a food composition or food additive composition for preventing or ameliorating an influenza virus infectious disease comprising an active ingredient of a plant-derived lactic acid bacterium.

Another object of the present invention is to provide a feed composition or feed additive composition for preventing or ameliorating an influenza virus infectious disease comprising as an active ingredient a plant-derived lactic acid bacterium.

Accordingly, the present invention provides, as a first preferred embodiment, an antiviral pharmaceutical composition for influenza virus containing Lactobacillus plantarum DSR M2 [Accession No .: KFCC-11432] or a culture thereof as an active ingredient.

At this time, the virus may be an influenza A virus of A / Korea / 01/2009 (H1N1).

The pharmaceutical composition for antiviral according to the above embodiment may be one for preventing or treating a disease caused by an influenza virus infection.

In addition, the disease caused by the viral infection may be one of influenza, cold, sore throat, bronchitis, pneumonia, avian influenza, swine flu and chlorine influenza.

As a second preferred embodiment of the present invention, there is provided a food composition for preventing or ameliorating an influenza virus infection disease containing Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432) or a culture thereof as an active ingredient.

The present invention provides, as a third preferred embodiment, a food additive composition for preventing or ameliorating an influenza virus infectious disease containing Lactobacillus plantarum DSR M2 [Accession No .: KFCC-11432] or a culture thereof as an active ingredient .

As a fourth preferred embodiment of the present invention, there is provided a prophylactic composition for preventing or ameliorating an influenza virus infection disease comprising Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432) or a culture thereof as an active ingredient.

As a fifth preferred embodiment of the present invention, there is provided a feed composition for preventing or ameliorating an influenza virus infection disease comprising Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432) or a culture thereof as an active ingredient.

As a sixth preferred embodiment of the present invention, there is provided a feed additive composition for preventing or ameliorating an influenza virus infectious disease containing Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432) or a culture thereof as an active ingredient .

As a seventh preferred embodiment, the present invention provides a fermented food for preventing or ameliorating an influenza virus infectious disease containing Lactobacillus plantarum DSR M2 [Accession No .: KFCC-11432] or a culture thereof as an active ingredient.

The present invention provides, as a preferable eighth embodiment, a composition for disinfection or cleaning of influenza virus containing Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432) or a culture thereof as an active ingredient.

The composition for disinfection or cleaning according to the above embodiments may be used as a disinfectant, a kitchen detergent, a laundry detergent, a vegetable or vegetable detergent, or a hand cleaner.

Since the Lactobacillus plantarum DSR M2 of the present invention is excellent in antiviral activity against influenza virus, the pharmaceutical composition containing the same as an active ingredient can be used as an effective ingredient for preventing or treating influenza, cold, sore throat, bronchitis, Flu, swine flu, chlorine flu, and the like. Lactobacillus plantarum DSR M2, which exhibits the antiviral activity described above, may be usefully used in beverage, fermented food, health functional food, and the like, food composition, food additive composition, feed composition or feed additive composition.

1 is a photomicrograph showing the antiviral activity of influenza virus of Lactobacillus plantarum DSR M2 of the present invention.

Hereinafter, the present invention will be described in more detail.

The Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432P) of the present invention isolated from kimchi survived at least 85% at pH 2.5 and was found to have strong acid resistance and to exhibit 90% or more of NaCl 15% (v / v) Has a strong salt tolerance and survival rate of 100% at oxgall 3% (v / v).

The active ingredient of the present invention is a culture solution containing or not containing live cells, dried germs, dead cells or cells of the plant Lactobacillus plantarum DSR M2.

In the present invention, dead cells are killed dead plants by culturing the plant Lactobacillus plantarum DSR M2 of the present invention and then treating them with heating, ultrasonic waves, enzymes, pressures, acids and bases, And the like. If the fermentation broth is not contained, the fermentation broth may be filtered or centrifuged to recover the bacterial cells and kill the viable cells, or may first kill the cells and recover the killed cells from the culture broth.

In the present invention, when the lactobacillus plantarum DSR M2 is cultured, the composition of the culture medium and the culture conditions may be carried out according to a suitable culture medium and culture conditions known in the art. Such a culturing process can be easily adjusted according to the strain selected by those skilled in the art. These various methods of culturing are disclosed in various publications (e.g., James et al., Biochemical Engineering, Prentice-Hall International Editions).

For example, the plant Lactobacillus plantarum DSR M2 of the present invention derived from kimchi can be prepared by adding 0.01 to 3 parts by weight of each strain to 100 parts by weight of the plant medium. The vegetable medium may include 10 to 40 parts by weight of Chinese cabbage and 10 to 40 parts by weight of radish in 100 parts by weight of the vegetable medium, preferably 0.1 to 5 parts by weight of glucose and / or 0.1 to 5 parts by weight of yeast extract can do. Lactobacillus plantarum DSR M2 is inoculated to the plant medium and fermented at 25 to 40 DEG C for 2 to 5 days to obtain a fermentation broth containing the cells. The fermentation broth in which the cells are removed can be obtained by centrifuging the fermentation broth containing the cells So that only the supernatant can be obtained.

In the present invention, the active ingredient having antiviral activity against influenza virus is the Lactobacillus plantarum DSR M2 lactic acid bacterium, which is derived from a lactic acid bacterium which has been proven to be safe, and is used for preventing or treating diseases caused by influenza virus infection without fear of side effects A pharmaceutical composition, a food composition for preventing or improving an influenza virus infection disease, a food additive composition, a probiotics composition, a feed composition, a feed additive composition, a fermented food, and a composition for cleaning or disinfecting. Wherein said influenza virus is one type A influenza virus selected from the group consisting of H1N1 subtypes and H3N2 subtype A influenza viruses or one type B influenza virus selected from the group consisting of Victoria lineage and Yamagata lineage . (H1N1) pdm09-like virus, A / Hong Kong / 4801/2014 (H3N2) -like virus, B / Brisbane / 60 / 2013-like virus.

As used herein, " treatment " refers to the treatment or amelioration of symptoms, reduction of disease extent, delay or alleviation of disease progression, improvement, alleviation or stabilization of disease state, partial or complete recovery, It is used to mean both inclusive.

Examples of the diseases caused by the viral infection according to the present invention include diseases caused by influenza virus infection such as influenza, cold, sore throat, bronchitis, pneumonia, avian influenza, swine flu and chlorine influenza, It is not.

More specifically, the present invention provides an antiviral pharmaceutical composition for influenza virus containing, as a preferred embodiment, Lactobacillus plantarum DSR M2 (Accession No .: KFCC-11432P) or a culture thereof as an active ingredient.

The pharmaceutical composition may be formulated into oral formulations, and may be formulated into oral dosage forms such as, for example, solutions, suspensions, powders, granules, tablets, capsules, pills or extensions. When formulating each formulation, a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation can be added. Typically, it is a form for oral administration. At the time of formulation, one or more of carriers such as a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer and an antiseptic can be selected and used as an additive. Or more can be selected and used.

Examples of the diluent include lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol as the diluent, magnesium stearate or talc as the lubricant, polyvinylpyrrolidone as the binder, Or hydroxypropylcellulose are preferable. Examples of the disintegrant include carboxymethylcellulose calcium, sodium starch glycolate, polacrilin potassium, or crospovidone; examples of sweeteners include white sugar, fructose, sorbitol, or aspartame; stabilizers include sodium carboxymethylcellulose, Preferred examples of the antiseptic agent include methyl paraoxybenzoate, propyl paraoxybenzoate, and potassium sorbate.

In addition to the above components, natural additives such as natural flavors such as plum flavor, lemon flavor, pineapple flavor and herb flavor, natural fruit juice, natural coloring matters such as chlorophyllin and flavonoid, fructose, honey, sugar alcohol, sugar Or acidic agents such as citric acid and sodium citrate may be mixed and used. These formulations and the carriers and additives required for formulation are described in detail in Remington's Pharmaceutical Sciences (19 ^th ed., 1995).

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, it is preferable to administer the Lactobacillus plantarum DSR M2 of the present invention at a dose of 0.01 mg / kg to 10 g / kg, preferably 1 mg / kg to 1 g / kg per day, for a preferable effect. The administration may be carried out once a day or divided into several times. Thus, the dosage amounts are not intended to limit the scope of the invention in any manner.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.

In yet another preferred embodiment of the present invention, there is provided a food composition or food composition for preventing or ameliorating an influenza virus infectious disease comprising Lactobacillus plantarum DSR M2 [accession number: KFCC-11432P] or a culture thereof as an active ingredient An additive composition is provided.

The food composition may be manufactured as a health functional food such as a powder, a granule, a capsule, a suspension, an emulsion, a syrup, a liquid, an extract, and may be manufactured as a fermented food such as cheese, kimchi, fermented sausage, , Beverages, baby foods, dairy products, tea, jellies, and the like. It may also be used as a food additive composition necessary for the production of the food composition.

When the Lactobacillus plantarum DSR M2 of the present invention is contained in a food composition or a food additive composition, the amount thereof may be 0.01 to 15% by weight based on the total weight of the dried or solid food, and 0.02 To 10 g, preferably from 0.3 to 1 g.

When used as a food composition or food additive composition, may be formulated into conventional formulations known in the art, together with a pharmaceutically acceptable carrier or excipient. The pharmaceutically acceptable carrier or additive may be any carrier or additive known to be usable in the art for the preparation of the formulation to be prepared.

When the food composition of the present invention is prepared in a beverage form, there are no particular limitations on the liquid ingredient other than the above-mentioned lactobacillus plantarum DSR M2 of the present invention as an essential ingredient in the indicated ratios, and various flavors Or natural carbohydrate as an additional ingredient. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, polysaccharides such as maltose, sucrose, and the like, such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol, and erythritol. Natural flavors (tautatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the beverage of the present invention.

In addition, the food composition or food additive composition of the present invention may contain, in addition to the Lactobacillus plantarum DSR M2 of the present invention, which is used as an active ingredient, a flavor such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors , Colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, ≪ / RTI > In addition, the food composition or food additive composition of the present invention may contain, in addition to the Lactobacillus plantarum DSR M2 of the present invention, natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

In yet another preferred embodiment of the present invention, there is provided a feed composition or feed composition for preventing or ameliorating an influenza virus infectious disease comprising the above-mentioned Lactobacillus plantarum DSR M2 [Accession No .: KFCC-11432P] or a culture thereof as an active ingredient An additive composition is provided.

When Lactobacillus plantarum DSR M2 is used in a feed or feed additive composition, the composition may be 20 to 90% high concentrate or may be prepared in powder or granular form. The feed additive may be selected from the group consisting of organic acids such as citric acid, fumaric acid, adipic acid, lactic acid and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, alpha-tocopherol, Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, and the like. When used as a feed, the composition may be formulated in conventional feed form and may contain conventional feed ingredients. The feed additives and feeds may be selected from the group consisting of cereals, such as ground or crushed wheat, oats, barley, corn and rice; Vegetable protein feeds such as feeds based on rapeseed, beans and sunflower; Animal protein feeds such as blood, meat, bone meal and fish meal; A sugar or a milk product, for example, a dry component comprising various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like. The feed additive may be administered to animals singly or in combination with other feed additives in edible carriers. The feed additives can also be administered to the animal either as a top dressing or they can be mixed directly with the animal feed or in a separate oral form separate from the feed. When the feed additive is administered separately from an animal feed, it can be prepared in an immediate release or sustained release formulation, in combination with a pharmaceutically acceptable edible carrier as is well known in the art. Such edible carriers may be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive can be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form. When a liquid carrier is used, the feed additive can be a gelatin soft capsule, or a syrup or suspension, emulsion, or solution formulation. The feed may comprise any protein-containing organic fructose commonly used to meet an animal's dietary needs. These protein-containing flours usually consist of corn, soy flour, or corn / soy flour mix. The feed composition or feed additive composition may also contain, for example, preservatives, stabilizers, wetting or emulsifying agents, solution promoters, and the like. The feed additive composition may also be used by adding to the feed of the animal by soaking, spraying or mixing.

In yet another preferred embodiment of the present invention, there is provided a composition for disinfection or cleaning of influenza virus containing Lactobacillus plantarum DSR M2 (Accession No. KFCC-11432P) or a culture thereof as an active ingredient. The composition may be used in disinfectants, kitchen detergents, laundry detergents, vegetable or vegetable detergents, or hand cleaners, but is not limited thereto.

The disinfecting or cleaning compositions of the present invention may comprise one or more surfactants. The surfactant may be anionic, non-ionic, cationic, amphoteric or zwitterionic type, or a mixture thereof. Representative examples of anionic surfactants include linear alkylbenzenesulfonic acid salts (LAS), alkylsulfuric acid salts (AS), alpha olefin sulfonic acid salts (AOS), alcohol ethoxy sulfate (AES) or alkali metal salts of natural fatty acids. Examples of non-ionic surfactants include alkylpolyethylene glycol ethers, nonylphenol polyethylene glycol ethers, fatty acid esters of sucrose with glucose or esters of polyethoxylated alkyl glucosides.

The composition for disinfecting or cleaning according to the present invention can be suitably used for various purposes such as an abrasive, a bleaching agent, a surface active agent, a corrosion inhibitor, a metal blocker, a stain-repellent agent, a perfume, a stabilizer for enzymes and bleaching agents, Foam boosters, chelating agents, fillers, fabric softeners, and the like, as well as other detergent ingredients known in the art. In addition, the disinfecting or cleaning composition of the present invention may be formulated into any convenient form such as powder or liquid.

Hereinafter, the structure of the present invention will be described in more detail with reference to examples. It is to be understood, however, that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims. It is obvious that the present invention belongs to the claims.

[ Example ]

Manufacturing example  One: Lactobacillus Pantalum DSR  Culture of M2

To culture Lactobacillus plantarum DSR M2 isolated from kimchi, MRS medium [MRS, Difco .; 10 g of bovine peptone, 10 g of beef extract, 5 g of yeast extract, 20 g of glucose, 80 g of tween 80, 2 g of citric acid, 2 g of potassium diphosphate, 5 g of sodium acetate, 0.1 g of manganese sulfate, 0.05 g of magnesium sulfate, (DSM M2 [accession number: KFCC-11432P]), followed by incubation at 37 ° C for 24 hours. Subsequently, the Lactobacillus plantarum DSR M2 strain cultured in the third passage was centrifuged, and the cells were suspended in 10% skim milk and stored at -70 ° C.

Then, the lactic acid bacteria were inoculated into the MRS liquid medium and cultured at 37 占 폚 for 24 hours. The culture broth containing the cells was centrifuged at 4,000 rpm for 10 minutes at 4 ° C to obtain cells, which were then washed three times with sterilized PBS buffer solution. The washed cells were suspended in sterilized PBS buffer solution and heat-treated at 95 ° C for 10 minutes. The heat-treated bacterium was centrifuged at 4,000 rpm at 4 DEG C for 10 minutes to obtain cells, which were then suspended in 1 mL of sterilized PBS buffer solution. The suspension of this bacterium was used for the experiment while being stored at -20 ° C.

[ Test Example ]

Test Example  One: Lactobacillus Pantalum DSR  Experiment of antiviral activity against Influenza virus of Lactobacillus acidus M2

In order to analyze the antiviral activity against influenza virus causing the flu, Lactobacillus plantarum DSR M2 of Production Example 1 was heat-inactivated and used.

MDCK (Madin-Darby Canine Kidney) cells were purchased from ATCC USA and cultured in MEM (minimal essential medium) containing 10% fetal bovine serum (FBS). The temperature of the incubator was 37 ° C, Was maintained at 5%.

Influenza viruses were used from A / Korea / 01/2009 (H1N1), which was distributed by the National Institute of Health's Disease Control Headquarters.

(MDCK) (Madin-Darby Canine Kidney) cell line infected with the H1N1 subtype of influenza A virus (A / Korea / 01/2009) was inoculated with the inactivated Lactobacillus plantarum DSR M2 lactic acid bacteria of Preparation Example 1 Agar media (2% Oxoid agarose sol (in DMEM-F12)) in 5% CO ₂ and 37% incubator for 72 h in the presence of 5%, 5%, 2.5%, 1.25%, 0.625% After incubation for a time, the cells were stained with 0.1% (v / v) crystal violet to perform plaque assays.

The results of the antiviral activity were confirmed by a decrease in the ability of the influenza virus to form plaques formed in the MDCK cell line (decrease in diameter), and the results are shown in Fig. 1, the Lactobacillus plantarum DSR M2 lactic acid bacterium is represented by M2 using the last letter of the strain name.

As can be seen from FIG. 1, the Lactobacillus plantarum DSR M2 lactic acid bacteria of the present invention significantly inhibited plaque formation of influenza virus. It has been demonstrated that the decrease in plaque diameter observed at 10% and 5%, due to dose-dependent inhibition of plaque formation as the concentration of lactic acid bacteria decreases, is due to the antiviral efficacy of lactic acid bacteria.

Formulation examples or preparation examples for the composition of the present invention are illustrated below.

< Formulation example > Preparation of pharmaceutical preparations

1-1: Preparation of tablets

100 mg of the lyophilized powder of Lactobacillus plantarum DSR M2 of Production Example 1, 100 mg of corn starch, 100 mg of lactose and 97 mg of polyvinylpyrrolidone were homogeneously mixed and granulated by a wet granulation method, followed by mixing with 2 mg of magnesium stearate And one tablet was 400mg.

1-2: Preparation of capsules

100 mg of the lyophilized powder of the lactobacillus plantarum DSR M2 of Production Example 1, 100 mg of the corn starch, 100 mg of the lactose and 2 mg of the magnesium stearate were thoroughly mixed and filled in hard gelatin capsules according to a conventional preparation method of the capsules, .

< Manufacturing example  2> Manufacturing of beverages

First, the mixed fruit juice syrup was prepared by mixing 30 wt% of liquid sugar, 13 wt% of fructose, 2.5 wt% of white sugar, 2.5 wt% of brown sugar, 10.9 wt% of concentrated juice concentrate, 1.0 wt% of pectin, 0.1 wt% of fresh fruit mix essence, The mixture was stirred at ~ 35 ° C, heat-treated by UHT (sterilized at 135 ° C for 2 seconds), and cooled. Then, 30.4% by weight of the mixed fruit juice syrup prepared by the above method and 0.1% by weight of the lyophilized powder of the lactobacillus plantarum DSR M2 of Preparation Example 1 and 69.5% by weight of the remaining purified water were combined and homogenized at 150 bar, And then packaged in a small container such as a glass bottle or a plastic bottle to prepare a beverage.

< Manufacturing example  3> Preparation of fermented sausage

2% by weight of a powder obtained by lyophilization of Lactobacillus plantarum DSR M2 in Production Example 1 was added to a mixture of 90% by weight of raw material, 0.25% by weight of pepper, 0.05% by weight of garlic, 0.05% by weight of rosemary, 2.8% And added to the sausage raw material containing the remaining amount of purified water, followed by fermentation at 15 to 30 DEG C for 3 months to produce fermented sausage.

< Manufacturing example  4> Health Functional Foods ( Hard capsule )

100 mg of the lyophilized powder of Lactobacillus plantarum DSR M2 of Production Example 1

Vitamin mixture quantity

70 비 of vitamin A acetate

Vitamin E 1.0mg

0.13 mg of vitamin B ₁

0.15 mg of vitamin B ₂

Vitamin B ₆ 0.5 mg

0.2 g of vitamin B ₁₂

Vitamin C 10mg

10 μg of biotin

Nicotinic acid amide 1.7 mg

50 엽 of folic acid

Calcium pantothenate 0.5mg

Mineral mixture quantity

1.75 mg ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Calcium phosphate diphosphate 55 mg

Potassium citrate 90mg

Calcium carbonate 100 mg

24.8 mg of magnesium chloride

The materials of the above composition were mixed in a high-speed spin mixer. 10 parts by weight of sterilized purified water was added to 100 parts by weight of the mixture, and the mixture was granulated into granules having a diameter of 1 to 2 mm. The molded granules were dried in a vacuum drier at 40 to 50 DEG C and then passed through 12 to 14 mesh to prepare uniform granules. The granules thus prepared were extruded in suitable amounts and filled into hard capsules to prepare hard capsule products.

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily changed, and the above components may be mixed The granules can then be prepared and used in the manufacture of health functional foods according to conventional methods.

< Manufacturing example  5> Production of feed

3% by weight of Lactobacillus plantarum DSR M2 of Preparation Example 1 and 97% by weight of degreasing agent were simply mixed and dried at 40 ° C or lower, and the dried mixture was pulverized to prepare a feed.

Claims (12)

Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) A pharmaceutical composition for antiviral against influenza A virus comprising as an active ingredient.
delete 2. The antiviral pharmaceutical composition according to claim 1, wherein the composition is for preventing or treating a disease caused by an influenza virus infection.
4. The antiviral pharmaceutical composition according to claim 3, wherein the disease caused by the virus infection is one of influenza, cold, sore throat, bronchitis, pneumonia, avian influenza, swine flu and chlorophyll.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) which contains as an active ingredient an effective component for preventing or ameliorating influenza A virus infection.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) A food additive composition for preventing or ameliorating an influenza A virus infection disease comprising as an active ingredient.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1), which contains Aspergillus oryzae as an active ingredient.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) (H1N1), which contains Aspergillus oryzae as an active ingredient, for the prevention or amelioration of an influenza A virus infection of type A / Korea / 01/2009 (H1N1).
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) A feed additive composition for preventing or ameliorating an influenza A virus infection disease comprising as an active ingredient.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) A fermented food for preventing or ameliorating influenza A virus infectious disease comprising as an active ingredient.
Lactobacillus plantarum DSR M2 (accession number: KFCC-11432P) or its culture which is resistant to acid at pH 2.5, salt tolerance at 15% (v / v) NaCl and 3% (v / v) A / Korea / 01/2009 (H1N1) for the disinfection or cleaning of type A influenza virus.
12. The composition of claim 11, wherein the composition is used in a disinfectant, a kitchen detergent, a laundry detergent, a vegetable or vegetable detergent, or a hand cleaner.

Images